Integrated Annual Report

Overview

The report presents Aurobindo Pharma's third integrated annual report for FY25, covering April 2024-March 2025. It highlights consolidated revenue of ₹31,724 Cr, a 22% carbon-emissions reduction, approximately 14% renewable energy use, and 98,512 MWh of renewable power. The company completed a double materiality assessment aligned with CSRD and disclosed a consolidated Scope 3 inventory of 3,60,221 tCO2e across eight categories. It also reports 27,707 permanent employees, approximately 13% women representation, and Board-level sustainability oversight.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 April 2024 – 31 March 2025
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level
CDP score

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services